Heather Gulish
Nurse Practitioner · St Clair Shores, MINPI 1679538318
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,100 of the $9,556 with a category attached, or 74.3%. 31 manufacturers reported payments, led by Medtronic at 34.1% of the total. Reporting peaked in 2024 at $3,764 and has fallen 50.4% since, to $1,866 in 2025. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $39.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- AstraZeneca$612
- Sumitomo Pharma America, Inc.$607
- Johnson & Johnson$522
- AbbVie$463
- Merck$443
- plus $4K from 25 others
What the payments were for
- Travel & lodging$2,21223%
- Food & beverage$7,10074%
- Education$2443%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 33 | $3,259 |
| AstraZeneca | 9 | $612 |
| Sumitomo Pharma America, Inc. | 29 | $607 |
| Johnson & Johnson | 5 | $522 |
| AbbVie(2 entities) | 27 | $463 |
| Merck | 13 | $443 |
| Endo USA, Inc. | 11 | $319 |
| Coloplast | 7 | $290 |
| Pfizer | 5 | $283 |
| Myriad Genetic Laboratories, Inc. | 8 | $270 |
| Antares Pharma, Inc. | 12 | $231 |
| Astellas Pharma US Inc | 11 | $224 |
| Bayer | 5 | $224 |
| Endo Pharmaceuticals Inc. | 9 | $214 |
| Dendreon Pharmaceuticals LLC | 4 | $209 |
| Halozyme Inc | 6 | $207 |
| Urogen Pharma, Inc. | 8 | $188 |
| Olympus America Inc. | 10 | $146 |
| Procept Biorobotics Corporation | 2 | $141 |
| Axonics, Inc. | 3 | $140 |
| Verity Pharmaceuticals Inc. | 4 | $87 |
| 180 Medical, Inc. | 4 | $74 |
| Tolmar, Inc. | 4 | $72 |
| Clarus Therapeutics Inc. | 4 | $62 |
| Immunitybio, Inc. | 3 | $59 |
| Ferring Pharmaceuticals Inc. | 1 | $58 |
| Boston Scientific | 1 | $49 |
| Ambu Inc. | 1 | $36 |
| Urovant Sciences Inc | 2 | $28 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Calyxo, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,556 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 25 | $17,832 |
| MyrbetriqMirabegron | 24 | $16,688 |
| Mirabegron ErMirabegron | 14 | $6,408 |
| Estradiol | 20 | $1,275 |
| Testosterone Cypionate | 25 | $1,153 |
| Tamsulosin Hcl | 37 | $1,019 |
| Methenamine Hippurate | 12 | $942 |
| Cephalexin | 160 | $580 |
| Finasteride | 19 | $424 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 41 | $320 |
| WaterWater For Irrigation,sterile | 11 | $99 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $54 |
| Ciprofloxacin Hcl | 15 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $607 | $17,83225 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $16,68824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in St Clair Shores
- Davida KrugerDetroit$739K
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
- Debra DegraffGrand Rapids$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.